Summary GSK has signed an oligonucleotide licensing agreement with China-based SiranBio worth up to $1 billion to develop SA030, a Phase 1-stage ALK7-targeting therapy for metabolic disease and abdominal fat reduction. What Happened GSK agreed to pay SiranBio $55 million…
Summary CellCentric has raised $220 million in a Series D financing to advance inobrodib, an oral p300/CBP inhibitor for multiple myeloma, supporting ongoing Phase 2 studies and planned Phase 3 development. What Happened The financing will fund late-stage clinical development…
Summary Protagonist Therapeutics has opted out of its 50:50 US profit-sharing agreement with Takeda for rusfertide, granting Takeda full US commercial rights in exchange for up to $475 million in near-term payments and substantial downstream milestones and royalties. What Happened…
Summary Eli Lilly has entered a definitive agreement to acquire Ajax Therapeutics in a deal worth up to $2.3 billion to secure AJ1-11095, a first-in-class Type II JAK2 inhibitor for myelofibrosis and polycythemia vera, positioning Lilly in the next-generation JAK…
Summary Regeneron has entered into a ‘most favored nation’ (MFN) drug-pricing agreement with the White House, aligning certain drug prices with Medicaid benchmarks. The move reflects increasing policy pressure on pharmaceutical pricing rather than a scientific or clinical development. What…
Summary Merck has entered a ~$1 billion enterprise agreement with Google Cloud to expand use of AI across its R&D and operational infrastructure, marking a major investment in AI-enabled drug development capabilities. What Happened Merck signed a long-term deal with…
Summary Beeline Therapeutics has emerged from stealth with approximately $300 million in financing, representing one of the largest recent biotech startup launches and signaling renewed investor appetite for platform-driven company creation. What Happened The Bain-backed company officially launched with ~$300M…
Summary Terremoto Biosciences has raised $108 million in a Series C financing to advance its covalent targeted protein degradation platform, including AKT1-targeting degraders into clinical development. What Happened The company secured $108M to support progression of its degrader pipeline, with…
Summary Neomorph has raised $100 million to advance its molecular glue platform, reinforcing investor confidence in next-generation targeted protein degradation technologies. What Happened The company secured $100M in financing to expand development of its molecular glue therapeutics platform. The announcement…
Summary Pfizer announced the closure of its South San Francisco research site, citing underutilization and broader pressures in the biotech funding environment. The move reflects ongoing post-pandemic restructuring across large pharmaceutical companies and signals shifts in R&D footprint strategy. What…
